0001415889-24-019462.txt : 20240710 0001415889-24-019462.hdr.sgml : 20240710 20240710161128 ACCESSION NUMBER: 0001415889-24-019462 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240708 FILED AS OF DATE: 20240710 DATE AS OF CHANGE: 20240710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leyman Barbara CENTRAL INDEX KEY: 0002028309 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38662 FILM NUMBER: 241110098 MAIL ADDRESS: STREET 1: C/O SUTRO BIOPHARMA, INC. STREET 2: 111 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUTRO BIOPHARMA, INC. CENTRAL INDEX KEY: 0001382101 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452441988 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-392-8412 MAIL ADDRESS: STREET 1: 111 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: SUTRO BIOPHARMA INC DATE OF NAME CHANGE: 20061127 4 1 form4-07102024_080725.xml X0508 4 2024-07-08 0001382101 SUTRO BIOPHARMA, INC. STRO 0002028309 Leyman Barbara C/O SUTRO BIOPHARMA, INC. 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 false true false false Chief Business Dev. Officer 0 Stock Option (Right to Buy Common Stock) 3.04 2024-07-08 4 A 0 125000 0 A 2034-07-08 Common Stock 125000 125000 D Restricted Stock Units (RSUs) 2024-07-08 4 A 0 100000 0 A 2028-07-08 Common Stock 100000 100000 D The option vests as to 25% of the total award on July 8, 2025, then in equal monthly installments over the following three years, subject to the reporting person's continued service to the issuer on each vesting date. Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. The RSUs vest as to 1/4th of the total award annually beginning on July 8, 2025, subject to the reporting person's continued service to the issuer through each vesting date. /s/ Edward C. Albini as attorney-in-fact for Barbara Leyman 2024-07-10